Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Income from Continuing Operations (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Income from Continuing Operations for 4 consecutive years, with 4303000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 80.36% year-over-year to 4303000.0, compared with a TTM value of 108712000.0 through Sep 2025, up 181.64%, and an annual FY2024 reading of 92000.0, up 99.97% over the prior year.
  • Income from Continuing Operations was 4303000.0 for Q3 2025 at Atara Biotherapeutics, down from 2387000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 153823000.0 in Q4 2022 and bottomed at 88105000.0 in Q1 2022.
  • Average Income from Continuing Operations over 4 years is 16002066.67, with a median of 21909000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations tumbled 485.08% in 2023, then soared 220.13% in 2024.
  • Year by year, Income from Continuing Operations stood at 153823000.0 in 2022, then tumbled by 139.3% to 60450000.0 in 2023, then skyrocketed by 220.13% to 72618000.0 in 2024, then plummeted by 105.93% to 4303000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for ATRA at 4303000.0 in Q3 2025, 2387000.0 in Q2 2025, and 38010000.0 in Q1 2025.